UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38594 TILRAY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4310622 (State or other jurisdiction of in ...

Tilray, Inc. (NASDAQ:TLRY) Q1 2022 Earnings Conference Call October 7, 2021 8:30 AM ET Company Participants Irwin Simon – Chairman and Chief Executive Officer Carl Merton – Chief Financial Officer Berrin Noorata – Chief Corporate Affairs Officer Conference Call Participants Owen Bennett – Jefferies Vivien Azer – Cowen and Company Andrew Carter – Stifel John Zamparo – CIBC World Markets Michael Lavery – Piper Sandler Aaron Grey – Alliance Global Partners Pablo Zuanic – Cantor Fitzgerald Glenn Mattson – Laden ...

INVESTOR PRESENTATION LEADING THE GLOBAL CANNABIS INDUSTRY JULY 2021 ATILRAY DISCLAIMER 2021© TILRAY | Certain statements contained in this press release constitute "forward-looking statements" within the meaning of federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions based on expectations and projections about future events and are not statements of historical fact. You can identify forward-looking statements by the use of forwa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38594 TILRAY, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-4310622 (State or other jurisdiction of incorporatio ...

Financial Data and Key Metrics Changes - Net income rose to $33.6 million compared to a net loss of $84.3 million in the prior year [56][71] - Net revenue increased 25.3% to $142.2 million in Q4 over the prior year period [61] - Adjusted EBITDA increased to $40.8 million compared to $5.8 million in 2020, reflecting an improvement of 603% [76] - Free cash flow of $3.3 million was generated in Q4, marking a significant milestone for the company [56][73] Business Line Data and Key Metrics Changes - Cannabis revenue in Q4 was $53.7 million, up from $39.6 million in the same period of the prior year [61] - SweetWater's net revenues were $15.9 million, while Manitoba Harvest generated $5.8 million in essentially one month of activity [61] - Adjusted cannabis gross profit increased to $23.9 million in Q4 compared to $18.9 million in the prior year [64] - Adjusted beverage alcohol gross profit was $10.6 million in Q4, with a gross margin of 66.5% [68] Market Data and Key Metrics Changes - The average gross selling price of adult-use cannabis decreased to $2.98 per gram in Q4 from $3.90 per gram in the prior year [62] - The average gross selling price of medical cannabis decreased to $4.54 per gram in Q4 from $4.95 in the prior year [63] - The Canadian market share is currently at 16%, with a goal to reach 30% by fiscal year 2024 [16] Company Strategy and Development Direction - The company aims to achieve $4 billion in revenue by 2024, driven by growth in adult-use, medical cannabis, and new product offerings [8][84] - Strategic partnerships and strong relationships with provincial boards and retail partners are emphasized to drive brand loyalty and growth in Canada [19] - The company plans to leverage its international presence, particularly in Europe, to grow its medical cannabis business [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on growth opportunities despite challenges posed by COVID-19 [10][11] - The reopening of markets is expected to improve sales dynamics, particularly for SweetWater [100] - Management highlighted the importance of consumer education and marketing changes in Canada to drive market share growth [95] Other Important Information - The company has a strong cash position of $488 million as of May 31, 2021, to support working capital and business plans [11][75] - The company has already achieved $35 million in synergies from the business combination, ahead of the anticipated pace [57][45] - The company is positioned to benefit from potential U.S. federal legalization, with plans to explore acquisitions in the consumer goods sector [84][104] Q&A Session Summary Question: Will there be permits issued to Tilray for continued growth and production in Germany? - Management confirmed that there are opportunities for additional tenders and production in Germany, especially with potential legalization from the Green Party [82] Question: Will SweetWater THC drinks be available in Canada, and are there plans to expand SweetWater to California? - Management stated that THC drinks will be available in Canada and that expansion into California is planned with a new facility in Fort Collins, Colorado [83] Question: How will Tilray benefit from pending federal legalization in the U.S.? - Management highlighted plans to grow through adult-use and medical cannabis, aiming for significant sales growth in the U.S. market post-legalization [84] Question: How is the company thinking about U.S. assets moving forward? - Management indicated a focus on acquiring consumer goods assets and MSOs, with a goal of achieving $1 billion to $1.5 billion in sales in the U.S. market [89][90] Question: What underpins the logic behind the 30% market share aspiration for 2024? - Management emphasized the need for increased consumer awareness, store openings, and innovation in products to achieve the market share goal [92][94]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38594 Tilray, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4310622 (State or other jurisdiction of inc ...

Aphria Inc. (APHA) Q3 2021 Earnings Conference Call April 12, 2021 9:00 AM ET Company Participants Carl Merton - Chief Financial Officer Irwin Simon - Chief Executive Officer Conference Call Participants Owen Bennett - Jefferies Andrew Carter - Stifel Financial Tamy Chen - BMO Capital Markets Aaron Gray - Alliance Global Partners Pablo Zuanic - Cantor Fitzgerald John Zamparo - CIBC World Markets Matthew Bottomley - Canaccord Genuity Michael Lavery - Piper Sandler Operator Good morning. My name is Mariama a ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38594 TILRAY, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organizati ...

Financial Data and Key Metrics Changes - For the full year 2020, total revenue increased by 26% to $210.5 million, driven by significant growth in International Medical and Canadian Adult Use businesses [15][58] - Q4 2020 total revenue was $56.6 million, up 21% year-over-year, with robust growth in International Medical, Adult Use, and Canadian medical channels [57][79] - Adjusted EBITDA for Q4 2020 was positive $2.2 million, a significant improvement from an adjusted EBITDA loss of $35.6 million in Q4 2019 [79][80] - Gross margin for Q4 2020 increased to 29% from negative 121% in the same period last year, and 36.4% when excluding inventory valuation adjustments [73][74] Business Line Data and Key Metrics Changes - Canadian Adult Use revenue grew 50% to $83.8 million for the full year 2020, with Q4 revenues reaching $25.4 million, a 27% sequential increase [18][15] - International Medical sales revenue increased by 153% for the full year, reaching $33.9 million, with Q4 revenue up 44% to $11.7 million [28][58] - Manitoba Harvest revenue increased by 28% to $76.9 million for the full year, but Q4 revenue decreased by 18% to $15.3 million [40][63] Market Data and Key Metrics Changes - The Canadian Adult Use market saw a 50% year-over-year growth, with a significant increase in retail store count to 1,319 by the end of 2020 [19][25] - International Medical growth was primarily driven by performance in Germany and Australia, with expectations for further market share gains as the market expands [28][29] - The average net selling price per gram of cannabis in Q4 2020 was $5.97, a 118% increase from $1.88 in the same period in 2019 [66][69] Company Strategy and Development Direction - The company is focused on combining with Aphria to create the world's largest global cannabis company by revenue, emphasizing scale and product leadership [6][43] - The strategy includes expanding the product portfolio across all major cannabis categories and enhancing the presence in the U.S. market through established brands [48][49] - The company aims to leverage its European platform for international growth opportunities, particularly in the medical cannabis sector [47][38] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the adult use market, believing that temporary hurdles will not impede long-term growth [25][26] - The company is well-positioned to capitalize on the ongoing shift from the illicit market to the legal market, supported by increased accessibility and consumer acceptance [26][39] - Management highlighted the importance of operational improvements and cost-cutting measures that have positioned the company for future growth [13][78] Other Important Information - The company achieved approximately $57 million in annualized savings compared to Q4 2019, surpassing its original goal of $40 million [14][78] - The company ended Q4 2020 with cash and cash equivalents of approximately $189.7 million, an increase from $155.2 million at the end of Q3 2020 [82] - The company is committed to achieving approximately CAD$100 million in pre-tax synergies following the merger with Aphria [84] Q&A Session Summary Question: Focus on recreational business and sales trajectory - Management noted that growth was led by flower products, with good growth across all product lines, and emphasized the importance of maintaining relationships with provincial boards [92][93][95] Question: Management changes at Manitoba Harvest - Management explained that the shift to private label by a major customer impacted sales and margins, but they remain optimistic about regaining market share and expanding the CBD segment [99][100][106] Question: Forward commentary on Q1 sales and EBITDA - Management refrained from providing specific guidance due to the uncertainties related to COVID-19 but expressed bullishness about the business's current position and future opportunities [110][111] Question: Price points and market traction in adult use - Management indicated that high potency products continue to drive sales, with successful new product launches contributing to growth [114][115] Question: Stickiness in export markets - Management reported strong brand loyalty and market share growth in international markets, attributing this to the unique purchasing process in pharmaceutical markets [120][123]

Tilray, Inc. (NASDAQ:TLRY) Q3 2020 Earnings Conference Call November 9, 2020 5:00 PM ET Company Participants Raphael Gross - Investor Relations Brendan Kennedy - Chief Executive Officer Michael Kruteck - Chief Financial Officer Conference Call Participants Pablo Zuanic - Cantor Fitzgerald Aaron Grey - Alliance Global Partners Vivien Azer - Cowen Graeme Kreindler - Eight Capital Scott Fortune - ROTH Capital Partners Mike Hickey - The Benchmark Company Andrew Carter - Stifel Glenn Mattson - Ladenburg Bill Kir ...